Linker Information

General Information of This Linker

Linker ID	LIN0OUTRX
Linker Name	Formyl-Gly-Glu
Linker Type	Flexible reactive (thiol) linker
Antibody-Linker Relation	Cleavable
Structure
Structure	3D MOL		2D MOL
Formula	C9H13BrN2O6
Isosmiles	O=C(O)CCC(NC(=O)CNC(=O)CBr)C(=O)O
InChI	InChI=1S/C9H13BrN2O6/c10-3-6(13)11-4-7(14)12-5(9(17)18)1-2-8(15)16/h5H,1-4H2,(H,11,13)(H,12,14)(H,15,16)(H,17,18)
InChIKey	LLODMEXPRFSSOV-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight	325.115	Polar area	132.8
	Complexity	18	xlogp Value	-1.0683
	Heavy Count	18	Rot Bonds	8
	Hbond acc	4	Hbond Donor	4

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

ABBV-154 [Phase 2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05068284	Clinical Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): aim-cd.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04972968	Clinical Status	Phase 2
Clinical Description	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of ABBV-154 in subjects with polymyalgia rheumatica (PMR) dependent on glucocorticoid treatment.
Experiment 3 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT04888585	Clinical Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsdmards).
Experiment 4 Reporting the Activity Date of This ADC				[4]
*Related Clinical Trial*
NCT Number	NCT05556226	Clinical Status	Phase 1
Clinical Description	A phase 1 study in healthy subjects to evaluate the relative bioavailability of ABBV-154.

References

Ref 1	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD, NCT05068284
Ref 2	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, NCT04972968
Ref 3	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs), NCT04888585
Ref 4	A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154, NCT05556226